Source comparison
Tirzepatide MOTS-C Metabolic Optimization: Protocol Comparison
Glycemic Control Focus 10–15mg weekly 5mg 3×/week Tirzepatide once weekly, MOTS-c M/W/F Insulin resistance reversal, fasting glucose reduction −2.0 to −2.5% over 24 weeks Best for individuals with HbA1c >7.5% seeking pharmaceutical-grade glucose normalization
This comparison does not assign a generated winner or score.
- Glycemic Control Focus
- 10–15mg weekly
- 5mg 3×/week
- Tirzepatide once weekly, MOTS-c M/W/F
- Insulin resistance reversal, fasting glucose reduction
- −2.0 to −2.5% over 24 weeks
- Best for individuals with HbA1c >7.5% seeking pharmaceutical-grade glucose normalization alongside mitochondrial function restoration
- Body Composition Optimization
- 12.5–15mg weekly
- 10mg 3×/week
- Visceral fat reduction, skeletal muscle glucose uptake
- −1.5 to −2.0% over 24 weeks
- Prioritizes weight loss and adipose remodeling. Higher MOTS-c dose enhances muscle retention during caloric deficit created by tirzepatide
- Metabolic Flexibility Protocol
- 7.5–10mg weekly
- 15mg 2×/week
- Tirzepatide once weekly, MOTS-c Tuesday/Friday
- Mitochondrial biogenesis, AMPK activation, metabolic adaptation
- −1.2 to −1.8% over 24 weeks
- Lower tirzepatide dose reduces GI side effects while MOTS-c carries the metabolic workload. Ideal for research into mitochondrial aging and metabolic resilience
- This table reflects dosing ranges used in clinical and preclinical research. Not personal medical recommendations. All protocols require physician oversight, baseline metabolic panels (HbA1c, fasting insulin, lipid profile), and monitoring for adverse events including pancreatitis, gallbladder disease, and thyroid C-cell hyperplasia.